PPC
AZN icon

Park Place Capital’s AstraZeneca AZN Stock Holding History

Park Place Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-176
Closed -$32.4K – 853
2025
Q4 		$32.4K Buy
176
+36
+26% +$6.31K 0.01% 395
2025
Q3 		$21.5K Hold
140
– – ﹤0.01% 448
2025
Q2 		$20K Sell
140
-1,150
-89% -$161K ﹤0.01% 476
2025
Q1 		$190K Hold
1,290
– – 0.05% 188
2024
Q4 		$169K Sell
1,290
-531
-29% -$74.3K 0.05% 217
2024
Q3 		$284K Hold
1,821
– – 0.08% 176
2024
Q2 		$284K Buy
1,821
+531
+41% +$79.9K 0.09% 177
2024
Q1 		$175K Hold
1,290
– – 0.06% 250
2023
Q4 		$174K Buy
1,290
+753
+140% +$97.9K 0.07% 241
2023
Q3 		$72.7K Sell
537
-1,150
-68% -$157K 0.02% 410
2023
Q2 		$241K Buy
1,687
+763
+83% +$112K 0.07% 221
2023
Q1 		$128K Hold
924
– – 0.04% 303
2022
Q4 		$125K Buy
+924
New +$116K 0.04% 312

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Park Place Capital's AZN Position: Q1 2026 in Review

Park Place Capital sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 176 shares — an estimated $32.4K sold.

Park Place Capital first reported a position in AZN in Q4 2022 and held it in 13 quarters. The position peaked at $284K in Q2 2024. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Park Place Capital reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Park Place Capital sold 176 AstraZeneca shares in Q1 2026, an estimated $32.4K.
  • Park Place Capital first reported a position in AstraZeneca in Q4 2022 and held it in 13 quarters.
  • Park Place Capital's AstraZeneca position peaked at $284K in Q2 2024.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Park Place Capital's 13F filing for Q1 2026, filed 9 Apr 2026.